Evert B. Schimmelpennink's Insider Trades & SAST Disclosures
Evert B. Schimmelpennink's most recent trade in LENZ Therapeutics Inc. was a trade of 4,200 Common Stock done at an average price of $1.0 . Disclosure was reported to the exchange on March 7, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Evert B. Schimmelpennink.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| LENZ Therapeutics Inc. | Evert B. Schimmelpennink | Director, President, CEO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.04 per share. | 07 Mar 2025 | 4,200 | 49,200 | - | 1.0 | 4,368 | Common Stock |
| LENZ Therapeutics Inc. | Evert B. Schimmelpennink | Director, President, CEO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2025 | 4,200 | 337,906 | - | - | Stock Option (right to buy) | |
| LENZ Therapeutics Inc. | Evert B. Schimmelpennink | Director, President, CEO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2025 | 279,100 | 279,100 | - | - | Stock Option (right to buy) | |
| LENZ Therapeutics Inc. | Evert B. Schimmelpennink | Director, President, CEO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.04 per share. | 22 Jul 2024 | 45,000 | 45,000 | - | 1.0 | 46,800 | Common Stock |
| LENZ Therapeutics Inc. | Evert B. Schimmelpennink | Director, President, CEO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jul 2024 | 45,000 | 342,106 | - | - | Stock Option (right to buy) | |
| Contineum Therapeutics Inc... | Evert B. Schimmelpennink | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 29,500 | 29,500 | - | - | Stock Option (right to buy) | |
| LENZ Therapeutics Inc. | Evert B. Schimmelpennink | Director, President, CEO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 475,000 | 475,000 | - | - | Stock Option (right to buy) | |
| LENZ Therapeutics Inc. | Evert B. Schimmelpennink | Director, President, CEO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 387,106 | 387,106 | - | - | Stock Option (right to buy) | |
| LENZ Therapeutics Inc. | Evert B. Schimmelpennink | Director, President, CEO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 315,864 | 315,864 | - | - | Stock Option (right to buy) | |
| LENZ Therapeutics Inc. | Evert B. Schimmelpennink | Director, President, CEO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 82,723 | 82,723 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges